Cargando…
Diffuse skeletal pain after administration of alendronate
BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and p...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941618/ https://www.ncbi.nlm.nih.gov/pubmed/20927253 http://dx.doi.org/10.4103/0253-7613.68435 |
_version_ | 1782186920201158656 |
---|---|
author | Ozaras, Nihal Rezvani, Aylin |
author_facet | Ozaras, Nihal Rezvani, Aylin |
author_sort | Ozaras, Nihal |
collection | PubMed |
description | BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. Musculoskeletal pain may be an important side effect in these patients. We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate. CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis. |
format | Text |
id | pubmed-2941618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-29416182010-10-06 Diffuse skeletal pain after administration of alendronate Ozaras, Nihal Rezvani, Aylin Indian J Pharmacol Case Report BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. Musculoskeletal pain may be an important side effect in these patients. We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate. CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis. Medknow Publications 2010-08 /pmc/articles/PMC2941618/ /pubmed/20927253 http://dx.doi.org/10.4103/0253-7613.68435 Text en © Indian Journal of Pharmacology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Ozaras, Nihal Rezvani, Aylin Diffuse skeletal pain after administration of alendronate |
title | Diffuse skeletal pain after administration of alendronate |
title_full | Diffuse skeletal pain after administration of alendronate |
title_fullStr | Diffuse skeletal pain after administration of alendronate |
title_full_unstemmed | Diffuse skeletal pain after administration of alendronate |
title_short | Diffuse skeletal pain after administration of alendronate |
title_sort | diffuse skeletal pain after administration of alendronate |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941618/ https://www.ncbi.nlm.nih.gov/pubmed/20927253 http://dx.doi.org/10.4103/0253-7613.68435 |
work_keys_str_mv | AT ozarasnihal diffuseskeletalpainafteradministrationofalendronate AT rezvaniaylin diffuseskeletalpainafteradministrationofalendronate |